Medically reviewed on November 15, 2017.
Applies to the following strengths: 50 mg
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Hodgkin's Disease
-Classical Hodgkin lymphoma consolidation: 1.8 mg/kg IV (maximum 180 mg) over 30 minutes every 3 weeks; initiate therapy within 4 to 6 weeks post-auto-HSCT or upon recovery from auto-HSCT; administer every 3 weeks until a maximum of 16 cycles, disease progression, or unacceptable toxicity
-Relapsed classical Hodgkin lymphoma: 1.8 mg/kg IV (maximum 180 mg) over 30 minutes every 3 weeks; administer every 3 weeks until disease progression or unacceptable toxicity
-Relapsed primary cutaneous anaplastic large cell lymphoma or DC30-expressing mycosis fungoides: 1.8 mg/kg IV (maximum 180 mg) over 30 minutes every 3 weeks; administer every 3 weeks until a maximum of 16 cycles, disease progression, or unacceptable toxicity
-Relapsed systemic anaplastic large cell lymphoma: 1.8 mg/kg IV (maximum 180 mg) over 30 minutes every 3 weeks; administer every 3 weeks until disease progression or unacceptable toxicity
-The dose for patients weighing greater than 100 kg should be calculated based on a weight of 100 kg.
-Classical HL after failure of autologous hematopoietic stem cell transplantation (auto-HSCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates
-For the treatment of patients with classical HL at high risk of relapse or progression as post-auto-HSCT consolidation
-For treatment of patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen
Renal Dose Adjustments
-CrCl 30 mL/min or greater: Initial: No adjustment recommended.
-CrCl less than 30 mL/min: Not recommended.
Liver Dose Adjustments
-Mild hepatic impairment (Child-Pugh A): 1.2 mg/kg (maximum 120 mg) IV over 30 minutes every 3 weeks; the dose for patients weighing greater than 100 kg should be calculated based on a weight of 100 kg
-Moderate (Child-Pugh B) to severe (Child-Pugh C) hepatic impairment: Not recommended.
-New or worsening Grade 2 or 3 neuropathy: Hold dosing until improvement to Grade 1 or baseline, then restart at 1.2 mg/kg (maximum of 120 mg) IV over 30 minutes.
-Discontinue therapy for Grade 4 peripheral neuropathy.
-Grade 3 or 4 neutropenia: Hold dosing until resolution to baseline or Grade 2 or lower; consider G-CSF prophylaxis for subsequent cycles in patients who experience Grade 3 or 4 neutropenia in the previous cycle.
-Recurrent Grade 4 neutropenia despite the use of G-CSF prophylaxis: Consider discontinuation or dose reduction of 1.2 mg/kg (maximum 120 mg) IV over 30 minutes.
US BOXED WARNING:
Progressive Multifocal Leukoencephalopathy (PML): John Cunningham virus (JCV) infection resulting in PML and death has been reported with this drug. First onset of symptoms occurred at various times from initiation of therapy, with some cases occurring within 3 months of initial exposure. In addition to therapy with this drug, other possible contributory factors include prior therapies and underlying disease that may cause immunosuppression.
Safety and efficacy have not been established in patients younger than 18 years.
Consult WARNINGS section for additional precautions.
Data not available
-This drug should be administered under the supervision of a physician experienced in the use of anti-cancer agents.
-Proper procedures for handling and disposal of anticancer drugs should be followed.
-Refer to the manufacturer product information.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about brentuximab
- Brentuximab Side Effects
- During Pregnancy
- Dosage Information
- Drug Interactions
- Support Group
- En Español
- 0 Reviews
- Drug class: CD30 monoclonal antibodies
Other brands: Adcetris